Information, Community and Research Funding

The mission of The EHE Foundation is to seek treatments and a cure for Epithelioid Hemangioendothelioma (EHE) by increasing awareness, pursuing scientific research, advocating for and supporting EHE patients, and bridging information between researchers, providers and patients.

HOW TO FIGHT EHE

CONNECT

Signup for our email newsletter below to hear about the latest research, fundraisers and events. Follow us on Facebook. Don’t forget to hit that Like button!

DONATE

Donate and encourage others to donate as well. Attend and support one of the fundraising events held each year. To view the funding needed see our Current Research Page

SHARE

Share the EHE Foundation with the world. Let them know that we are here and that we need funding to fight EHE. Tell them your story and encourage them to help.

Giving Tuesday is Upon Us!
Tuesday, November 27, 2018

During this past week, we have featured several touching stories of those affected by EHE (see below). These stories have one thing in common, which all EHE patients can relate to: there are no standard treatments for EHE. Money raised by The EHE Foundation during #Giving Tuesday (Nov 27th) will address this common issue and give doctors of EHE patients options for evidence-based treatments.

We are planning a multi institutional international project. EHE is highly unpredictable and exhibits a broad variety of clinical behaviors, so we must include as many EHE patients as possible to obtain reliable information. The math is simple: amount of funding we have for this study = more hospitals will participate = more EHE cases will be included = data obtained will be more comprehensive and accurate.

The main goal of the study is to assess:

  • Local and systemic treatment modalities applied to EHE across various EHE locations and response to these treatments
  • Difference in progression between interventional treatment and “wait and watch” approach • Clinical and radiological presentations indicative of EHE progression
  • Utilized symptoms management and the impact on quality of life

Would you like a simple way to help explain what we do here at The EHE Foundation? Feel free to use this bifold. You can click the images below to enlarge and print it to share with those not online. Remember, your donation will be DOUBLED on #GivingTuesday (Nov 27th)! "

Fight EHE Giving Tuesday Graphic

#GivingTuesday is a global movement to celebrate and encourage giving after Thanksgiving, Black Friday, and Cyber Monday. We are thrilled to announce that donations to The EHE Foundation will be DOUBLED on #GivingTuesday (Tues, Nov 27th) by our generous supporters. This is your chance to double your impact in helping those affected by this extremely rare cancer by hitting the “donate now” button on this page, donating through our Facebook Page, or by sending a check to The EHE Foundation, 1561 Hopi Ct, Hobart, WI 54313.

Donations could also be TRIPLED if done through Facebook early on #GivingTuesday before the $7 million dollar matching from Facebook and PayPal is reached. Matching will start at 8:00am EST (5:00am PST) on Tues, Nov 27, 2018. Donations up to $250k per nonprofit and $20k per donor are eligible to be matched, so $7 million won’t last long!

Donations could be QUADRUPLED! Many companies match employee donations dollar for dollar, and some will even double or triple gift amounts. Check with your employer for the chance to have an even greater impact with your donation. You can trust that your contribution will go a long way in continuing our forward momentum in research for EHE. We know you have many options when it comes to giving, but we hope you will support those affected by EHE.

FACES OF EHE

Leading up to #GivingTuesday (Nov 27th), we will feature a new “Faces behind EHE”each day. We want you to meet some of the extraordinary people behind this unpredictable and often fatal cancer. On #GivingTuesday, your donation to The EHE Foundation will be doubled!

Hannah Kiner

Hannah Kiner

“My name is Hannah Kiner. I live in Harrisburg, PA and I am a mommy to a 2 year old little boy. I like doing arts & crafts, dancing, traveling, outdoor adventuring, and spending time with my family. I am a member of the Westshoremen Senior Color Guard, am an Advocate for Mental Health Awareness, and when I am able to I do service work with Hope in Haiti. I was diagnosed with EHE when I was 27 years old after nearly a decade of being considered a “mystery patient”. When I first found out I had EHE I did…

Read More

IMPORTANT EHE NEWS & TRIALS

The Pledge, Edition 14

We warmly welcome all our readers to this fourteenth edition of “The Pledge”, the quarterly newsletter of the EHE Group. We hope you enjoy this newsletter, covering the third quarter of 2018.

 

Trametinib Trial

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery.

ClinicalTrials.gov Identifier:  NCT03148275

For the last several years Dr.Brian Rubin has been working on unlocking genetic driving mechanism behind EHE progression. His work resulted in identification of a pathway directly involved in supporting of EHE genetic malfunction. During the Lab experiments, Dr Rubin was able to disrupt this pathway with MEK inhibitor.

The clinical trial uses MEK inhibitor Mekinist. The purpose of the study to verify that what Dr.Rubin observed in his Lab actually translates in clinical effect in EHE patients. It is a multi institutional study which makes it very easy for enrollment in different parts of the country. You can see more information using following link.

https://clinicaltrials.gov/ct2/show/NCT03148275


Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

ClinicalTrials.gov Identifier: NCT03331250

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).

-The drug involved in this study is Eribulin

In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE.

Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules

https://clinicaltrials.gov/ct2/show/NCT03331250